Alnylam Pharmaceuticals
ALNY
#812
Rank
โ‚น2.907 T
Marketcap
โ‚น21,730
Share price
0.05%
Change (1 day)
-45.74%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): โ‚น506.74

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น535.19. In 2025 the company made an earnings per share (EPS) of โ‚น199.37.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น506.74154.18%
2025โ‚น199.37
2023-โ‚น341.63-62%
2022-โ‚น899.0929.03%
2021-โ‚น696.82-3.36%
2020-โ‚น721.01-8.48%
2019-โ‚น787.797.67%
2018-โ‚น731.6639.74%
2017-โ‚น523.5812.94%
2016-โ‚น463.5838.84%
2015-โ‚น333.89-32.88%
2014-โ‚น497.45259.44%
2013-โ‚น138.40-31.25%
2012-โ‚น201.30

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
โ‚น644.55 20.43%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น184.17-65.59%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น4,056 657.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น254.53-147.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น70.65-113.20%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น8.71-101.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น60.97-88.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-โ‚น322.28-160.22%๐Ÿ‡บ๐Ÿ‡ธ USA